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Objective: To study the interactions of colistin (MIC 2 mg/L) at concentrations of 0.5 and 5 mg/L with ceftazidime (1 and 
75 mg/L, MIC 0.5 mg/L), aztreonam (1 and 30 mg/L, MIC 0.12 mg/L), meropenem (1 and 25 mg/L, MIC 0.03 mg/L), 
gentamicin (1 and 10 mg/L, MIC 2 mg/L), piperacillin (5 and 100 mg/L, MIC 4 mg/L) and ciprofloxacin (0.25 and 4 mg/L, 
MIC 1 mg/L) using a representative strain of Pseudomonas aeruginosa isolated from a cystic fibrosis patient. 
Methods: The method used was a bacterial time kill curve with single agents and combinations. Using inocula of 
lo6 CFU/mL, multiple sampling was performed over 6 h and in triplicate. The AUBKC of the time versus viable count 
curve, with single agents and combinations of agents, was taken as the endpoint for comparison. 
Results: For colistin plus ceftazidime, colistin plus aztreonam, colistin plus meropenem and colistin plus ciprofloxacin, 
the pattern was for al l  the combinations (high or low concentrations) to produce smaller AUBKCs than single agents. In 
experiments using a bacteriostatic agent such as ceftazidime, the AUBKCs (log CFU/pL per h) for colistin 0.5 mg/L or 
5 mg/L alone were 32.320.8 or 12.720.5, and for ceftazidime 1 mg/L or 75 mg/L alone they were 24.321.5 or 20.9k2.7. 
Combinations of colistin 0.5 mg/L plus either ceftazidime 1 mg/L or 75 mg/L produced AUBKCs of 23.821.8 or 16.1 mg/L. 
Combinations of colistin 5 mg/L plus ceftazidime 1 mg/L or 75 mg/L produced AUBKCs of 12.220.8 or 8.721.0. The 
AUBKCs for colistin 5 mg/L plus 75 mg/L are significantly smaller than those for the single agents, indicating synergy. 
In experiments using the bactericidal agent ciprofloxacin, the AUBKCs (log CFU/mL per h) for colistin 0.5 mg/L or 5 mg/L 
alone were 33.621.9 or 11.2?2.4, and for ciprofloxacin 0.25 mg/L or 4 mg/L alone they were 32.821.3 or 5.0k0.7. 
Combinations of colistin 0.5 mg/L plus either ciprofloxacin 0.25 mg/L or 4 mg/L produced AUBKCs of 32.220.9 or 4.321.4. 
Combinations of colistin 5 mg/L plus ciprofloxacin 0.25 mg/L or 4 mg/L produced AUBKCs of 10.7k1.5 or 4.2~0.6. 
Although combination AUBKCs were smaller than those for single agents, in no case did this reach statistical significance 
(p<0.05). 
Conclusions: These studies indicate that addition of colistin to other antipseudomonal drugs tends to produce smaller 
AUBKCs and hence greater killing of Pseudomonas aeruginosa than monotherapy. 
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Colistin has been available since the 1950s for clinical 
use in the tleatment of~ram-negative infection In 
the 1960s it was largely replaced in clinical practice, first 
by aminoglycosides and then later by p-lactams, with 
ever improving in vitro activity against Gram-negative 
bacteria. The last decade has, however, seen increasing 
resistance in Gram-negative bacteria, especially Pseudo- 
motias aemginosa and Acinetobacter spp. 
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Colistin retains excellent in vitro activity even for 
l? aevtrgirzosa isolates from patients with cystic fibrosis [2] 
and is commonly administered by nebulizer to these 
patients, but also by the intravenous route [3,4]. In 
such clinical situations, patients are almost invariably 
receiving other antimicrobials, and the potential inter- 
actions between colistin and these agents have been 
poorly studied, most often using the checkerboard 
technique [5,6]. This method has its supporters [7] but 
has been criticized by others because of poor repro- 
ducibility and the use of arbitrary interpretative criteria 
[8,9]. We recently proposed another method of 
studying antimicrobial-antimicrobial interactions using 
bacterial time lull curves, with multiple sampling over 
6-8 h followed by calculation of the area under the 
bacterial time killing curve (AUBKC) to compare the 
bactericidal activity of agents as monotherapies or in 
combination. In our test system we use pharmaco- 
kinetically achievable serum concentrations [lo]. 
In this study we used bacterial time kill curves with 
both high and low pharmacokinetically achievable 
concentrations of colistin, plus ceftazidime, aztreonam, 
meropenem, piperacillin, gentamicin or ciprofloxacin, 
to study interactions assessed by the use of AUBKC as 
an endpoint, but also ‘classical’ criteria [I 11. 
MATERIALS AND METHODS 
Bacterial strains 
A single strain of l? aenrginosa, recovered from a cystic 
fibrosis patient, was used in the study. The strain was 
stored at -70°C until used. 
Antimicrobial agents 
The following antimicrobial agents were used: colistin 
sulfomethate sodium (Pharmax, Bexley, UK) at 0.5 and 
5 nig/L; ciprofloxacin (Bayer, Newbury, UK) at 0.25 
and 4 mg/L; gentamicin (David Bull Laboratories, 
Wanvick, UK) at 1 and 10 mg/L; piperacillin (Lederle 
Laboratories, Maidenhead, UK) at 5 and 100 mg/L; 
ceftazidime (Glaxo Laboratories Ltd, Greenford, UK) 
at 1 and 75 mg/L; aztreonam (Bristol Myers Squibb 
Pharmaceutical Ltd, Dublin, Ireland) at 1 and 30 mg/L; 
and meropenem (Zeneca Pharma, Wilmslow, UK) at 
1 and 25 mg/L. 
Time kill curve method 
The time kill curve methods were performed as 
described elsewhere [11]. IsoSensitest broths (20 mL) 
(Unipath, Basingstoke, UK) were inoculated to give a 
final inoculum of 10” CFU/mL. For each anti- 
microbial, drugs were incorporated in nine broths, the 
agent alone in four and at the concentrations given 
above in four, plus a growth control. These were then 
sampled, and diluted as necessary, and viable counts 
were performed using a spiral plater (Spiral Systems, 
Don Whitley, Shipley, UK) at time 0, 45 min, and then 
every 20 min up to 3 h, and every 45 min up to 6 h, 
on nutrient agar plates (Difco, West Molesey, UK). 
Viable counts were read manually after incubation at 
37°C. The study was performed in triplicate. 
Statistical analysis 
Time kill curves were drawn by plotting loglo 
CFU/mL against time (h), using the software package 
GraphPad Prism (GraphPad Software Inc., San Diego, 
USA). Data were log transformed and a baseline 
removed to compensate for the variability of the tech- 
nique. AUBKCs were then calculated and compared 
using Student’s t-test. 
RESULTS 
The results of a single experiment are shown in Figure 
1. This shows the time kill kinetics of colistin alone 
and colistin plus ceftazidime, aztreonam, meropenem, 
piperacillin, gentamicin or ciprofloxacin. The MICs 
for the strain used were: colistin 2 mg/L; ceftazidime 
0.5 mg/L; aztreonam 0.12 mg/L; meropenem 0.03 
mg/L, piperacillin 4 mg/L; gentamicin 3 mg/L; and 
ciprofloxacin 1 mg/L. 
Calculation of the AUBKCs showed that colistin 
alone was more bactericidal at a concentration of 
5 mg/L (smaller AUBKC) than 0.5 mg/L. This was 
not true of ceftazidime, aztreonam, meropenem or 
piperacillin which were more or less equipotent at high 
or low concentrations (Table 1). Gentamicin and 
ciprofloxacin also had smaller AUBKCs at low concen- 
trations than high. With all the six agents tested, the 
addition of colistin at  a concentration of 5 mg/L 
increased the amount of killing, with low, high or both 
concentrations of the second drug. Ceftazidime and 
aztreonam increased killing in combination with 
colistin, and this was significantly greater than for either 
colistin or the second agent alone. Although not 
reaching statistical significance, there was a trend for 
other combinations to have smaller AUBKC values 
than single agents (Table 1). 
According to ‘classical’ interpretative criteria for 
synergy in time kill kinetic plots, i.e. the combination 
is > 2  log more active at 74 h of incubation than the 
most active individual agent [ l l ] ,  then only colistin 
5 mg/L plus ceftazidime 1 or 75 mg/L showed synergy 
in all three replicates. Colistin 5 mg/L also showed 
synergy with meropenem 1 mg/L or gentamicin 
1 mg/L in two out of three replicates, and colistin 
0.5 mg/L showed synergy in one of three replicates 
with ceftazidime 1 or 75 mg/L (data not shown). 
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Figure 1 Time kill kinetics of colistin (C) at concentration of 0.5 mg/L (0.5) and 5 mg/L (5) plus: (a) ceftazidlme (CEF) at 
concentrations of 1 mg/L (1) and 75 mg/L (75); (b) aztreonam (AZT) at concentrations of 1 mg/L (1) and 30 mg/L (30); 
(c) meropenem (MER) at concentrations of 1 mg/L (1) and 25 mg/L (25); (d) piperacan (PIP) at concentrations of 5 mg/L 
(5) and 100 mg/L (100); (e) gentamicin (GEN) at concentrations of 1 mg/L (1) and 10 mg/L (10); (t) ciprofloxacin (CIP) at 
concentrations of 0.25 mg/L (0.25) and 4 mg/L (4). GC is the growth control. 
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Table 1 Areas under the bacterial time kill curves for colistin alone, second agents alone and  combinations 
Area under bacterial time kill curve 
(0-6 h) (log CFU/ml per h) (meanfstandard deviation) 
Second drug Colistin 0 mg/L Colirtin 0.5 mg/L Colistin 5 mg/L 
Ceftazidime 
0 mg/L - 34.220.8 12.720.5 
1 mg/L 24.321.5 23.8k 1.8 12.2k0.8 
75 mg/L 20.922.7 16.12 1 .0” 8.721 .Ob 
Aztreonam 
0 mg/L - 34.2k0.8 12.720.5 
30 mg/L 22.022.7 18.820.7 9.920.8h 
0 mg/L - 32.2& 1.0 11.722.5 
25 mg/L 13.1224 10.725.0 7.353.3” 
0 mg/L - 33.621.9 11.2k l .4  
5 mg/L 33.723.0 77 ()+? -I. 7 4 . 8 2  1 . O I  
100 mg/L 26.021.5 23.724.0 12.221.5~ 
0 mg/L - 33.42 1 .o 10.62 1.9 
1 mg/L 33.722.0 30.323.0 1 2.0 2 1.6” 
10 mg/L 11.123.1 10.9+1.2 8.4*1.1 
0 mg/L - 33.621.9 11.223.4 
4 mg/L 5.Ok0.7 4.321.4 4.220.6 
1 mg/L 24.821.1 34.8 2 1.1 11.0k0.3b 
Meropenem 
1 mg/L 16.323.8 14.42 4.3 9.1 t 3 2  
Piperacillin 
Gentamicin 
Ciprofloxacin 
0.25 mg/L 32.82 1.3 32.220.9 10.72 1 .Sa 
~ ~~~ ~~ ~~ ~ 
”Combination with colistin gave a significantly smaller AUC than second drug alone (p<0.05).  
Combination gave a significantly smaller AUC than either colistin or second drug alone (pi0.05). 
DISCUSSION 
These data are in broad agreement with others in 
showing that colistin, like aminoglycosides, quinolones 
and carbapenems, has bactericidal action against 
I? acniginosa [12]. However, it is less easy to compare 
our findings with previous data on antibiotic inter- 
actions with colistin. Checkerboard results have led to 
the suggestion that colistin plus gentamicin (using sub- 
inhibitory concentrations) is synergistic; synergy or 
addition was observed with colistin plus ceftazidime or 
inipeneni, and antagonism with colistin plus cipro- 
floxacin [5,6,13]. However, it is also known that 
comparison of checkerboard results with those from 
time kill curves results in less than 50% agreement, 
even when the experiments were done by the same 
workers [5]. It is therefore unsurprising that we failed 
to confirm antagonism between colistin and cipro- 
floxacin. Indeed, our data based on AUI3KC calculations 
showed greater killing by the combinations than by 
the individual agents. Conibinations of colistin and 
ceftazidime or aztreonam demonstrated synergy accord- 
ing to statistical comparisons of AUBKC: that is, the 
combination was more active than the individual 
agents alone. This was supported by use of ‘classical’, 
though arbitrary, interpretative criteria for colistin 
plus ceftazidime but not for colistin plus aztreonam. 
Previously, we showed that the AUBKC was the most 
robust measure of the overall pattern of bacterial killing 
in a time kill kinetic plot [lO]. This parameter can also 
be used for statistical comparisons, and is thus pre- 
ferable to the previously used criteria. 
In conclusion, this work showed no evidence of 
antagonism between colistin and any of the agents 
tested. Addition of colistin at high concentration 
improves killing of I? aeruginosu compared to most of 
the second agents tested, especially at low concen- 
trations, and synergy was observed with colistin plus 
ceftazidime or aztreonam. 
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